Clinical Determinants of Successful Omalizumab Therapy in Severe Allergic Asthma Patients: 4-Year-Long, Real-Life Observation

References

• Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2020 Available from: www.ginasthma.org. Accessed 530, 2020.
   Google Scholar
• Mapa Potrzeb Zdrowotnych MPZ ((Health Need Maps). Avaiable from mz.www.gov.pl. Accessed 530,2020.
   Google Scholar
• Jahnz-Różyk K, Lis J, Warchoł M, Kucharczyk A. Clinical and economic impact of a one-year treatment with omalizumab in patients with severe allergic asthma within a drug programme in Poland. BMC Pulm Med. 2018;18(1):48. doi:10.1186/s12890-018-0610-z29548318
   PubMed Web of Science ®Google Scholar
• Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;(1):CD003559.24414989
   PubMed Web of Science ®Google Scholar
• Schatz M, Rosenwasser L. The allergic asthma phenotype. J Allergy Clin Immunol Pract. 2014;2(6):645–648. (). doi:10.1016/j.jaip.2014.09.00425439351
   PubMed Web of Science ®Google Scholar
• Akar-Ghibril N, Casale T, Custovic A, Phipatanakul W. Allergic endotypes and phenotypes of asthma [published correction appears in J Allergy Clin Immunol Pract. 2020 May;8(5):1779]. J Allergy Clin Immunol Pract. 2020;8(2):429–440. doi:10.1016/j.jaip.2019.11.00832037107
   PubMed Web of Science ®Google Scholar
• Corry DB, Kheradmand F. Induction and regulation of the IgE response. Nature. 1999;402(6760 Suppl):B18–23. doi:10.1038/3503701410586891
   PubMed Web of Science ®Google Scholar
• Alhossan A, Lee CS, MacDonald K, Abraham I. “Real-life” effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis. J Allergy Clin Immunol Pract. 2017;5(5):1362–1370.e2. doi:10.1016/j.jaip.2017.02.00228351783
   PubMed Web of Science ®Google Scholar
• Mansur AH, Srivastava S, Mitchell V, Sullivan J, Kasujee I. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: study of efficacy and safety. Respir Med. 2017;124:36–43. doi:10.1016/j.rmed.2017.01.00828284319
   PubMed Web of Science ®Google Scholar
• Humbert M, Taille C, Mala L, et al. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J. 2018;51(5):1702523. doi:10.1183/13993003.02523-201729545284
   PubMed Web of Science ®Google Scholar
• van Bragt J, Adcock IM, Bel EHD, et al. Characteristics and treatment regimens across ERS SHARP severe asthma registries. Eur Respir J. 2020;55:1. doi:10.1183/13993003.01163-2019
   Web of Science ®Google Scholar
• Cabrejos S, Moreira A, Ramirez A, et al. FENOMA study: achieving full control in patients with severe allergic asthma. J Asthma Allergy. 2020;13:159–166. doi:10.2147/JAA.S24690232440161
   PubMed Web of Science ®Google Scholar
• Kupryś-Lipińska I, Majak P, Molinska J, Kuna P. Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience. BMC Pulm Med. 2016;16(1):61. doi:10.1186/s12890-016-0224-227117315
   PubMed Web of Science ®Google Scholar
• Uddin M, Watz H, Malmgren A, Pedersen F. NETopathic Inflammation in Chronic Obstructive Pulmonary Disease and Severe Asthma. Front Immunol. 2019;10:47. doi:10.3389/fimmu.2019.0004730804927
   PubMed Web of Science ®Google Scholar
• Available from https://www.gov.pl/web/zdrowie/programy-lekowe. Accessed 830, 2020.
   Google Scholar
• NOTICE OF THE MINISTER OF HEALTH of 26 October 2012 on the list of reimbursed drugs, foodstuffs intended for particular nutritional uses and medical devices at the date of 1 November 2012. Available on http://www.mz.gov.pl/leki/refundacja/lista-lekow-refundowanych-obwieszczenia-ministra-zdrowia/obwieszczenie-ministra-zdrowia-z-dnia-26-pazdziernika-2012-r. Accessed on 530, 2020.
   Google Scholar
• McDonald VM, Hiles SA, Godbout K, et al. Treatable traits can be identified in a severe asthma registry and predict future exacerbations. Respirology. 2019;24(1):37–47. doi:10.1111/resp.1338930230137
   PubMed Web of Science ®Google Scholar
• Brusselle G, Michils A, Louis R, et al. “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med. 2009;103(11):1633–1642. doi:10.1016/j.rmed.2009.06.01419619998
   PubMed Web of Science ®Google Scholar
• Casale TB, Pacou M, Mesana L, Farge G, Sun SX, Castro M. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis. J Allergy Clin Immunol Pract. 2019;7(1):122–130.e1. doi:10.1016/j.jaip.2018.08.03630217529
   PubMed Web of Science ®Google Scholar
• Tzortzaki EG, Georgiou A, Kampas D, et al. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean “real-life” experience. Pulm Pharmacol Ther. 2012;25(1):77–82.22155001
   PubMed Web of Science ®Google Scholar
• Singh H, Peters JI, Kaur Y, Maselli DJ, Diaz JD. Long-term evaluation of response to omalizumab therapy in real life by a novel multimodular approach: the Real-life Effectiveness of Omalizumab Therapy (REALITY) study. Ann Allergy Asthma Immunol. 2019;1(5):476–482. doi:10.1016/j.anai.2019.07.026
   Web of Science ®Google Scholar
• MacDonald KM, Kavati A, Ortiz B, Alhossan A, Lee CS, Abraham I. Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018. Expert Rev Clin Immunol. 2019;15(5):553–569. doi:10.1080/1744666X.2019.157457130763137
   PubMed Web of Science ®Google Scholar
• Kallieri M, Papaioannou AI, Papathanasiou E, Ntontsi P, Papiris S, Loukides S. Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study. Postgrad Med. 2017;129(6):598–604. doi:10.1080/00325481.2017.132194528427296
   PubMed Web of Science ®Google Scholar
• Yorgancıoğlu A, Öner Erkekol F, Mungan D, et al. Long-term omalizumab treatment: a multicenter, real-life, 5-year trial. Int Arch Allergy Immunol. 2018;176(3–4):225–233. doi:10.1159/00048834929772578
   PubMed Web of Science ®Google Scholar
• Nurkić J, Al-Ahmad M, Maher A, Arifhodžić N, Jusufović E. Most common, real life factors affecting effectiveness of omalizumab asthma treatment: a 10-year study. Med Glas (Zenica). 2019;16(1):45–52.30589240
   PubMedGoogle Scholar
• Braunstahl GJ, Chlumský J, Peachey G, Chen CW. Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting. Allergy Asthma Clin Immunol. 2013;9(1):47. doi:10.1186/1710-1492-9-4724305549
   PubMed Web of Science ®Google Scholar
• Vennera Mdel C, Pérez De Llano L, Bardagí Set al., Omalizumab therapy in severe asthma: experience from the Spanish registry–some new approaches. J Asthma. 2012;49(4):416–422. doi:10.3109/02770903.2012.66825522443408
   PubMed Web of Science ®Google Scholar
• Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest. 2004;125(4):1378–1386. doi:10.1378/chest.125.4.137815078749
   PubMed Web of Science ®Google Scholar
• Wahn U, Martin C, Freeman P, Blogg M, Jimenez P. Relationship between pretreatment specific IgE and the response to omalizumab therapy. Allergy. 2009;64(12):1780–1787. doi:10.1111/j.1398-9995.2009.02119.x19627273
   PubMed Web of Science ®Google Scholar
• Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med. 2007;101(7):1483–1492. doi:10.1016/j.rmed.2007.01.01117339107
   PubMed Web of Science ®Google Scholar
• Busse WW. Are peripheral blood eosinophil counts a guideline for omalizumab treatment? STELLAIR Says No! Eur Respir J. 2018;51:5.
   Web of Science ®Google Scholar
• Casale TB, Chipps BE, Rosén K, et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018;73(2):490–497. doi:10.1111/all.1330228859263
   PubMed Web of Science ®Google Scholar
• Henriksen DP, Bodtger U, Sidenius K, et al. Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma: a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma. Allergy Asthma Clin Immunol. 2020;16(1):49. doi:10.1186/s13223-020-00442-032565844
   PubMed Web of Science ®Google Scholar